113,355 Shares in Enovis Corporation $ENOV Bought by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in Enovis Corporation (NYSE:ENOV) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 113,355 shares of the company’s stock, valued at approximately $2,346,000.

Other large investors have also bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after acquiring an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new stake in shares of Enovis in the 3rd quarter worth $83,435,000. Paradigm Capital Management Inc. NY raised its holdings in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after purchasing an additional 732,917 shares during the last quarter. River Road Asset Management LLC raised its holdings in shares of Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after purchasing an additional 46,289 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Enovis by 38.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after purchasing an additional 287,687 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: The acquisition would expand Enovis’ ASTRA enabling-technology platform into orthopedic surgical robotics, adding robotic automation, imaging and navigation capabilities. Management expects the combination to improve surgical precision and workflow efficiency while creating a broader platform for future growth. Enovis acquisition announcement
• Positive Sentiment: Wells Fargo lowered its Enovis price target to $33 from $39 but maintained an “overweight” rating. Citizens JMP also reduced its target, to $47 from $55, while retaining a “market outperform” rating. The continued positive ratings indicate analysts see substantial long-term upside despite near-term concerns.
• Neutral Sentiment: Enovis plans to pay approximately €155 million, or about $180 million, for eCential Robotics. The transaction is intended to bring eCential’s surgical robot to market and broaden Enovis’ orthopedic technology portfolio. Enovis to acquire eCential Robotics for €155 million
• Negative Sentiment: Investors reacted negatively because the deal is expected to pressure Enovis’ margins in 2027. The acquisition also introduces execution, commercialization and integration risks as the company invests in developing and scaling the surgical robotics business. Shares have declined sharply following the announcement. Enovis drops after eCential acquisition offer

Insider Transactions at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have acquired 3,200 shares of company stock worth $69,864. Insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. BMO Capital Markets set a $27.00 price target on shares of Enovis in a report on Tuesday. Citizens Jmp decreased their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. BTIG Research cut their target price on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a report on Wednesday. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enovis has an average rating of “Moderate Buy” and an average price target of $40.38.

Enovis Trading Down 1.3%

NYSE ENOV opened at $20.26 on Thursday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -1.05 and a beta of 1.31. Enovis Corporation has a one year low of $19.14 and a one year high of $34.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The business’s fifty day moving average is $25.63 and its 200-day moving average is $24.26.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same quarter last year, the business posted $0.79 EPS. Enovis’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.